ArticleOncoTargets and therapy2025
Risk of Residual Axillary Lymph Node Macrometastasis in Early Breast Cancer PATIENTS with One Positive Macrometastasis Sentinel Lymph Node.
Article in OncoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the risk factors for residual axillary lymph node macro-metastasis in early-stage breast cancer patients with a single macrometastasis sentinel lymph node (SLN). Methods: We retrospectively analyzed the clinical data of 119 breast cancer patients diagnosed between January 2018 and September 2023, each with one positive SLN stained with methylene blue, who subsequently underwent axillary lymph node dissection. The patients were divided into two groups based on the total number of SLNs identified: fewer than three and more than three. Fisher's exact test was used for statistical analysis between groups. Results: Among the 119 patients evaluated, 30 patients had a total of 2 sentinel lymph nodes, with 15 testing positive for residual axillary lymph nodes, yielding a positivity rate of 50.0%. Another 30 patients had 3 sentinel lymph nodes, with a positivity rate of 33.3%. An additional 32 patients each had 4 sentinel lymph nodes, with a positivity rate of 3.13%. Finally, 27 patients had 5 sentinel lymph nodes, with a 0% positivity rate. The positivity rate of axillary lymph nodes was significantly higher in the group with ≤ 3 sentinel lymph nodes (less SLN group) compared to the group with > 4 sentinel lymph nodes (more SLN group). Binary logistic regression analysis confirmed that the number of SLNs was the only significant predictor of residual lymph node macrometastasis. Conclusion: The number of sentinel lymph nodes (SLNs) is a key factor influencing the risk of residual axillary lymph node macrometastasis in early-stage breast cancer patients with one positive SLN. Identifying a higher number of SLNs (≥4) significantly lowers the risk of residual metastasis, supporting the use of thorough SLN mapping in these cases to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.